A radioligand assay follows a radioactively labelled molecule in a receptor-binding experiment. The detector measures a signal associated with the tracer; the interpretation depends on how the experiment distinguishes receptor-related binding from background. A lower binding signal is not automatically evidence that a peptide blocks a biological response.
Identify which binding question was measured
The Assay Guidance Manual distinguishes saturation experiments, which can estimate tracer affinity and binding capacity, from competition experiments, which examine how an unlabelled compound changes tracer binding. Specific binding is calculated from total binding after accounting for the defined nonspecific component.Assay Guidance Manual — Receptor Binding Assays for HTS and Drug Discovery (opens in a new tab)
Read the tracer identity first. It may be a labelled version of the compound of interest or a different ligand used to investigate the same receptor. The measured affinity of the tracer and the inferred affinity of a competitor are not the same result.
Also locate the receptor source: a membrane preparation, purified material or another system. The experiment’s evidence concerns that preparation and the conditions reported, not an unspecified receptor in every biological setting.
Terms such as binding inhibition describe an assay observation. To determine whether a compound activates or opposes signalling, look for a separate functional experiment.
Work from the defined specific signal
| Condition | Total | Nonspecific | Specific |
|---|---|---|---|
| Reference | 1,200 | 200 | 1,000 |
| Competitor | 700 | 200 | 500 |
In this simplified example, specific binding is 1,200 − 200 = 1,000 for the reference and 700 − 200 = 500 for the competitor condition. The specific signal falls by half, although the total signal does not.
The example assumes the displayed nonspecific values are appropriate for each condition. In an actual paper, inspect how that component was defined and measured rather than subtracting a convenient constant from every observation.
One fictional comparison does not establish an IC50. A concentration-dependent analysis, adequate observations and a justified model are needed to estimate the concentration associated with a specified reduction.
Read the assumptions behind an affinity value
The Assay Guidance Manual explains that converting a competition IC50 to Ki requires an appropriate binding model and information about the tracer, including its concentration and affinity. The conversion is not a relabelling of the observed midpoint.Assay Guidance Manual — Receptor Binding Assays for HTS and Drug Discovery (opens in a new tab)
Check whether the result is reported as an observed IC50, an inferred Ki or a saturation Kd. Preserve that label in your summary. A table containing all three should not rank them as if they were identical quantities.
Look for evidence that timing and material availability were considered. If the report leaves the binding conditions or analysis assumptions unclear, describe the estimate with that limitation rather than treating its decimal places as proof of certainty.
A curve with incomplete plateaus or unexplained changes in background deserves attention before its fitted number is interpreted. A numerical output can exist even when the experiment does not adequately define the desired parameter.
Keep binding separate from biological effect
For the fictional competitor, the supported description is a reduction in the defined tracer-binding signal under the reported conditions. It does not establish whether the competitor is an agonist, antagonist or another kind of modulator.
A separate response assay can address that next question, but its model, timing and outcome must be read in their own right. Agreement between binding and response measurements should be demonstrated rather than assumed.
When comparing studies, retain the receptor preparation, tracer and reported parameter. A familiar receptor name does not remove differences in the measurement system.
This produces a useful evidence note: what was bound or displaced, how the specific signal was obtained and what functional question remains unanswered.
Sources and further detail
- Assay Guidance Manual — Receptor Binding Assays for HTS and Drug Discovery (opens in a new tab)
Saturation, nonspecific binding and heterologous-competition interpretation read. Brief parameter definitions only; no operational protocol, radiochemical handling instructions or published example values reproduced. Detector-count example is original.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.